AKBA · Insider Trading
Akebia Therapeutics, Inc.
Every open-market purchase and sale reported by AKBA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-10 | John P. Butler | CEO and President | M | +350,000 | +$220.50K |
| 2026-07-01 | Erik Ostrowski | SVP, CFO, CBO & Treasurer | Sell | −56,019 | −$62.18K |
| 2026-06-22 | Myles Wolf | Director | A | +35,700 | — |
| 2026-06-22 | Michael W Rogers | Director | A | +35,700 | — |
| 2026-06-22 | Leanne M Zumwalt | Director | A | +35,700 | — |
| 2026-06-22 | Ron Frieson | Director | A | +35,700 | — |
| 2026-06-22 | Cynthia Smith | Director | A | +35,700 | — |
| 2026-06-22 | Adrian Adams | Director | A | +35,700 | — |
| 2026-04-03 | Philip J. Vickers | Director | A | +214,400 deriv. | — |
| 2026-03-05 | John P. Butler | CEO and President | Buy | +69,270 | +$86.59K |
| 2026-02-04 | Erik Ostrowski | SVP, CFO, CBO & Treasurer | Sell | −34,951 | −$48.58K |
| 2026-02-04 | Steven Keith Burke | SVP, Chief Medical Officer | Sell | −67,658 | −$94.04K |
| 2026-02-04 | Richard C Malabre | SVP, Chief Accounting Officer | Sell | −49,524 | −$68.84K |
| 2026-02-04 | John P. Butler | CEO and President | MIXED | −166,055 | −$227.31K |
| 2026-02-04 | Nicholas Grund | Chief Commercial Officer | Sell | −84,829 | −$117.91K |
| 2026-02-04 | Carolyn M. Rucci | SVP, Chief Legal Officer | Sell | −69,772 | −$96.98K |
| 2026-02-03 | Steven Keith Burke | SVP, Chief Medical Officer | A | +204,000 | — |
| 2026-02-03 | Carolyn M. Rucci | SVP, Chief Legal Officer | A | +190,000 | — |
| 2026-02-03 | Nicholas Grund | Chief Commercial Officer | A | +204,000 | — |
| 2026-02-03 | John P. Butler | CEO and President | A | +743,000 | — |
| 2026-02-03 | Richard C Malabre | SVP, Chief Accounting Officer | A | +79,000 | — |
| 2026-02-03 | Erik Ostrowski | SVP, CFO, CBO & Treasurer | A | +204,000 | — |
| 2025-07-01 | Erik Ostrowski | SVP, CFO, CBO & Treasurer | Sell | −41,314 | −$151.62K |
| 2025-06-11 | Ron Frieson | Director | A | +35,700 | — |
| 2025-06-11 | Leanne M Zumwalt | Director | A | +35,700 | — |
| 2025-06-11 | Steven C Gilman | Director | A | +35,700 | — |
| 2025-06-11 | Myles Wolf | Director | A | +35,700 | — |
| 2025-06-11 | Richard C Malabre | SVP, Chief Accounting Officer | MIXED | — | −$34.95K |
| 2025-06-11 | Michael W Rogers | Director | A | +35,700 | — |
| 2025-06-11 | Adrian Adams | Director | A | +35,700 | — |
| 2025-06-11 | Cynthia Smith | Director | A | +35,700 | — |
| 2025-06-05 | Richard C Malabre | SVP, Chief Accounting Officer | Sell | −13,334 | −$47.07K |
| 2025-03-04 | Steven Keith Burke | SVP, Chief Medical Officer | Sell | −7,144 | −$13.07K |
| 2025-03-04 | John P. Butler | CEO and President | Sell | −46,409 | −$84.93K |
| 2025-02-04 | Richard C Malabre | SVP, Chief Accounting Officer | MIXED | +54,798 | −$63.42K |
| 2025-02-04 | Erik Ostrowski | SVP, CFO, CBO & Treasurer | A | +194,900 | — |
| 2025-02-04 | Nicholas Grund | Chief Commercial Officer | MIXED | +139,279 | −$116.80K |
| 2025-02-04 | John P. Butler | CEO and President | MIXED | +556,750 | −$302.93K |
| 2025-02-04 | Steven Keith Burke | SVP, Chief Medical Officer | MIXED | +144,394 | −$106.06K |
| 2025-01-22 | Ron Frieson | Director | M | +20,100 | +$9.04K |
| 2024-07-02 | Erik Ostrowski | SVP, CFO, CBO & Treasurer | A | +350,000 | — |
| 2024-06-10 | Cynthia Smith | Director | A | +30,000 | — |
| 2024-06-10 | Michael W Rogers | Director | A | +30,000 | — |
| 2024-06-10 | Adrian Adams | Director | A | +30,000 | — |
| 2024-06-10 | Steven C Gilman | Director | A | +30,000 | — |
| 2024-06-10 | Ron Frieson | Director | A | +30,000 | — |
| 2024-06-10 | Leanne M Zumwalt | Director | A | +30,000 | — |
| 2024-06-10 | Myles Wolf | Director | A | +30,000 | — |
| 2024-05-14 | Michel Dahan | SVP, Chief Operating Officer | Sell | −34,840 | −$43.90K |
| 2024-05-14 | Nicole R. Hadas | SVP, Chief Legal Officer | Sell | −12,016 | −$15.14K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| John P. Butler | CEO and President | 3,878,492 | $1.65M |
| Steven Keith Burke | SVP, Chief Medical Officer | 948,432 | $402.80K |
| Erik Ostrowski | SVP, CFO, CBO & Treasurer | 616,616 | $261.88K |
| Carolyn M. Rucci | SVP, Chief Legal Officer | 588,378 | $249.88K |
| Nicholas Grund | Chief Commercial Officer | 561,750 | $238.58K |
| Richard C Malabre | SVP, Chief Accounting Officer | 299,390 | $127.15K |
| Adrian Adams | Director | 236,200 | $100.31K |
| Michael W Rogers | Director | 197,429 | $83.85K |
| Cynthia Smith | Director | 196,633 | $83.51K |
| Myles Wolf | Director | 169,081 | $71.81K |
| Ron Frieson | Director | 165,200 | $70.16K |
| Steven C Gilman | Director | 152,830 | $64.91K |
| Leanne M Zumwalt | Director | 145,100 | $61.62K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the AKBA quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.